Eupraxia Pharmaceuticals Closes $63.2 Million Offering

MT Newswires Live

2 hours ago

Eupraxia Pharmaceuticals (EPRX) said Friday it closed a public offering of about 7.6 million shares at $7 each, along with pre-funded warrants for roughly 1.4 million shares, raising roughly $63.2 million in gross proceeds.

The offering included full exercise of the underwriters' option to purchase additional shares.

The company plans to use the funds to advance development of EP-104GI, expand its pipeline into additional gastrointestinal indications and support R&D and business development. A portion of the proceeds will be used for general corporate purposes, according to the company.

Shares of Eupraxia were up 4.2% in recent trading.

Price: 8.46, Change: +0.34, Percent Change: +4.19

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2613926162"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613926162\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613926162?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-21 04:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613926162","market":"us","top_or_hot":-1,"title":"Eupraxia Pharmaceuticals Closes $63.2 Million Offering","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/EPRX\">Eupraxia Pharmaceuticals</a> (EPRX) said Friday it closed a public offering of about 7.6 million shares at $7 each, along with pre-funded warrants for roughly 1.4 million shares, raising roughly $63.2 million in gross proceeds.</p><p>The offering included full exercise of the underwriters' option to purchase additional shares.</p><p>The company plans to use the funds to advance development of EP-104GI, expand its pipeline into additional gastrointestinal indications and support R&amp;D and business development. A portion of the proceeds will be used for general corporate purposes, according to the company.</p><p>Shares of Eupraxia were up 4.2% in recent trading.</p><p>Price: 8.46, Change: +0.34, Percent Change: +4.19</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eupraxia Pharmaceuticals Closes $63.2 Million Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEupraxia Pharmaceuticals Closes $63.2 Million Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-21 04:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/EPRX\">Eupraxia Pharmaceuticals</a> (EPRX) said Friday it closed a public offering of about 7.6 million shares at $7 each, along with pre-funded warrants for roughly 1.4 million shares, raising roughly $63.2 million in gross proceeds.</p><p>The offering included full exercise of the underwriters' option to purchase additional shares.</p><p>The company plans to use the funds to advance development of EP-104GI, expand its pipeline into additional gastrointestinal indications and support R&amp;D and business development. A portion of the proceeds will be used for general corporate purposes, according to the company.</p><p>Shares of Eupraxia were up 4.2% in recent trading.</p><p>Price: 8.46, Change: +0.34, Percent Change: +4.19</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPRX","symbol_name":"Eupraxia Pharmaceuticals","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2613926162","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613926162","pubTimestamp":1771619762,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eupraxia Pharmaceuticals  said Friday it closed a public offering of about 7.6 million shares at $7 each, along with pre-funded warrants for roughly 1.4 million shares, raising roughly $63.2 million in gross proceeds.The offering included full exercise of the underwriters' option to purchase additional shares.The company plans to use the funds to advance development of EP-104GI, expand its pipeline into additional gastrointestinal indications and support R&D and business development. A portion of the proceeds will be used for general corporate purposes, according to the company.Shares of Eupraxia were up 4.2% in recent trading.Price: 8.46, Change: +0.34, Percent Change: +4.19","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EPRX":"Eupraxia Pharmaceuticals","BK4139":"生物科技"},"translate_title":"Eupraxia Pharmaceuticals完成6320万美元的发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPRX":1.5},"content_text":"Eupraxia Pharmaceuticals (EPRX) said Friday it closed a public offering of about 7.6 million shares at $7 each, along with pre-funded warrants for roughly 1.4 million shares, raising roughly $63.2 million in gross proceeds.The offering included full exercise of the underwriters' option to purchase additional shares.The company plans to use the funds to advance development of EP-104GI, expand its pipeline into additional gastrointestinal indications and support R&D and business development. A portion of the proceeds will be used for general corporate purposes, according to the company.Shares of Eupraxia were up 4.2% in recent trading.Price: 8.46, Change: +0.34, Percent Change: +4.19","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}